Humanised antibodies

Details Humanised antibodies Humanised antibodies

2007-07-10

2007-07-10

Huff, Sheela J. (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023530, C435S320100, C530S387300, C530S387100, C530S388220, C424S133100, C424S143100

Reexamination Certificate

active

10704352

ABSTRACT:
CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.

REFERENCES:
patent: 4348376 (1982-09-01), Goldenberg
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 323 806 (1989-07-01), None
patent: 0 328 404 (1989-08-01), None
patent: 0 365 209 (1990-04-01), None
patent: 0 403 156 (1990-12-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 682 040 (1995-11-01), None
patent: WO 89/07452 (1989-08-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/04381 (1992-03-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 92/15683 (1992-09-01), None
patent: WO 92/16553 (1992-10-01), None
Chothia, Cyrus and Lesk, Arthur M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”J. Mol. Biol., 196:901-917, (1987) (pp. 901 and 904).
Chothia, Cyrus, et al., “Conformations of immunoglobulin hypervariable regions,”Nature, 342:877-883, (1989).
Jones, Peter T., et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature, 321:522-525, (1986).
Queen, Cary, et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA, 86:10029-10033, (1989).
Riechmann, Lutz, et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, (1988).
Roberts, S., et al., “Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering,”Nature, 328:731-734, (1987).
Verhoeyen, Martine, et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,”Science, 239:1534-1536 (1988).
Ward, Sally E., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted fromEscherichia coli,” Nature, 341:544-546, (1989).
Chambers 20thCentury Dictionary (1973 Edition), p. 1128.

Affiliated with

Also associated with

Rating

Humanised antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanised antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanised antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3721354